3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
609
Carboplatin
376
Paclitaxel
283
Cisplatin
269
Gemcitabine
256
Pemetrexed
195
Bevacizumab
191
Docetaxel
190
Nivolumab
188
Injections
169
Cyclophosphamide
148
atezolizumab
138
Capecitabine
134
Fluorouracil
133
Oxaliplatin
132
Dexamethasone
129
durvalumab
114
Fulvestrant
114
130-nm albumin-bound paclitaxel
111
fludarabine
102
Cetuximab
101
Leucovorin
97
Rituximab
96
venetoclax
90
Lenalidomide
84
Prednisone
79
enzalutamide
78
Azacitidine
76
Irinotecan
73
Ipilimumab
73
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hizentra
×
1 year
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled